---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000689"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T05:14:43.819125+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cingulate reports FY 2024 net loss $15.5M; cash runway extended to Q4 2025, NDA for CTx-1301 targeted mid-2025

## Summary
- Cash and equivalents $12.2M (vs $52k Dec 2023); working capital improved to $7.5M from -$9.6M.
- Net loss narrowed to $15.5M from $23.5M in 2023; R&D expenses fell to $9.4M from $15.5M.
- Pre-NDA FDA meeting scheduled April 2, 2025; NDA submission for CTx-1301 targeted mid-2025.
- Phase 3 pediatric safety data showed no serious TEAEs across nine clinical trials.
- Raised $17.5M in capital in 2024 via public offering, warrant inducement, and promissory note.

## SEC filing metadata
- accession: 0001641172-25-000689
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000164117225000689/0001641172-25-000689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000164117225000689/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000689
- JSON: https://secwatch.observer/filing/0001641172-25-000689.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.